What Does PD-L1 Mean on a Pathology Report?
PD-L1 is a biomarker that can affect whether immunotherapy becomes part of the treatment plan.
Read Guide →Resources
These guides are written for the moment when a report, diagnosis, or treatment term suddenly becomes personal. Each article is designed to help patients and caregivers walk into the next appointment with more clarity and better questions.
PD-L1 is a biomarker that can affect whether immunotherapy becomes part of the treatment plan.
Read Guide →EGFR-positive lung cancer often changes the treatment conversation because targeted therapy may become an option.
Read Guide →HER2-positive breast cancer often changes treatment because HER2-targeted therapies may be available.
Read Guide →KRAS is a common mutation that can influence treatment choices differently depending on the cancer type.
Read Guide →MSI-high is a biomarker result that can be especially important when immunotherapy is being considered.
Read Guide →ALK-positive lung cancer often matters because the tumor may respond to specific targeted therapies.
Read Guide →BRCA can matter both for treatment decisions and for inherited cancer-risk conversations within a family.
Read Guide →Tumor grade describes how the cancer cells look compared with normal cells, not how far the cancer has spread.
Read Guide →Stage IIIA NSCLC often means the cancer is still in the chest but more locally advanced than many families expect.
Read Guide →Stage 4 means the cancer has spread beyond its original location to distant organs or distant sites.
Read Guide →Adenocarcinoma is a cancer subtype, not a stage or a prognosis by itself.
Read Guide →Negative margins generally mean the surgeon removed tissue whose edges did not show cancer under the microscope.
Read Guide →Lymphovascular invasion is a pathology finding that can help doctors understand how the cancer may behave.
Read Guide →Immunotherapy is cancer treatment that helps the immune system respond more effectively to the tumor.
Read Guide →Targeted therapy is cancer treatment aimed at a specific biomarker or pathway rather than fast-growing cells in general.
Read Guide →A cancer treatment denial is often the start of an appeal process, not the end of the road.
Read Guide →Appealing a Keytruda denial usually depends on showing why pembrolizumab is medically necessary in this exact cancer setting.
Read Guide →Clinical trial phases tell you what the study is trying to learn, not whether the trial is automatically a good or bad choice.
Read Guide →A pathology report becomes easier to handle when you stop trying to read every line at once and look for the decision-driving sections first.
Read Guide →A short, focused question list can change the quality of a first oncology appointment more than families realize.
Read Guide →